In conclusion, using DDR genes as probes we identified novel biomarkers for AML prognostication: co-expression of AIM2 and CDC42BPA genes and sole expression of POLQ. Overexpression of Polθ confers cellular resistance to various genotoxic cancer therapies (ionizing radiation, genotoxic chemotherapy drugs) [14]. This evidence concerns the gene AIM2 and acute myeloid leukemia.